Remove Article Remove Compounding Remove Pharmaceutical Companies
article thumbnail

How much does semaglutide cost per month?

The Checkup by Singlecare

The medication is available in both brand-name and compounded forms, although the compounded forms are not FDA approved. Compounded semaglutide is made by special compounding pharmacies rather than pharmaceutical companies. Learn more from our article on how to get Wegovy covered by insurance.

article thumbnail

New European monograph for Cannabis flower adopted

European Pharmaceutical Review

.” Implementing quality standards for medicinal cannabis Mikael Sodergren of Curaleaf International explained in an article published on EPR’s website last month: “there is a vast range of flavonoids, terpenoids, phytols and other compounds present at lower concentrations within the cannabis flower”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Adapting Customer Engagement Strategies to the COVID Landscape

Pharma Marketing Network

In office/in person sales promotion, the staple of pharmaceutical company activities, is simply not possible today with interactions reduced to the sporadic video or to telephone engagement. This will result in permanent shifts in how HCPs and patients interact with pharmaceutical companies.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023. These issues will be explored in the final article of this series.

FDA 98
article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccines 134
article thumbnail

Nine for 2023, part one: a reflection on inflection

pharmaphorum

This article is the first part of three and covers the first three of nine predictions, here focusing on global healthcare environmental challenges and what they mean for the pharmaceutical industry. More remains to be addressed, and not just by conventional pharmaceutical companies. Pharma’s starting to wake up to this.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. However, it is already clear that the investments will be gargantuan.